Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis

Trials

Volumn 21, Issue 1, 2020, Pages

  Mead, Gillian Elizabeth ^a   Graham, Catriona ^b   Billot, Laurent ^c   Näsman, Per ^d   Lundström, Erik ^e   Lewis, Steff ^f   Hankey, Graeme J ^g   Hackett, Maree L ^c   Forbes, John ^h   Dennis, Martin ⁱ  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h UNIVERSITY OF LIMERICK   (Ireland)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

AFFINITY; EFFECTS; FOCUS; Individual patient data meta analysis; Recovery; Stroke

Indexed keywords

FLUOXETINE; PLACEBO;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CLINICAL TRIAL PROTOCOL; DATA ANALYSIS; DATA PROCESSING; DRUG EFFECT; ETHNICITY; FIXED EFFECTS META ANALYSIS; FRACTURE; HUMAN; INDIVIDUAL PATIENT DATA ANALYSIS; META ANALYSIS; MOOD DISORDER; PREDICTION; PUBLICATION; RISK BENEFIT ANALYSIS; SEIZURE; STATISTICAL ANALYSIS; STATISTICIAN; STROKE PATIENT; SYSTEMATIC REVIEW; AGED; BRAIN ISCHEMIA; CONVALESCENCE; FEMALE; MALE; META ANALYSIS (TOPIC); METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

AGED; BRAIN ISCHEMIA; DATA INTERPRETATION, STATISTICAL; FEMALE; FLUOXETINE; HUMANS; MALE; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; RESEARCH DESIGN; STROKE; TREATMENT OUTCOME;

EID: 85096530969     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-020-04875-1     Document Type: Article

References (20)

1. Johnson W, Onuma O, Owolabi M, Sachdev S. Stroke: a global response is needed. Bull World Health Organ. 2016;94:634–634A. DOI: 10.2471/BLT.16.181636
2. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–602. DOI: 10.1016/S0140-6736(16)31678-6
3. Chollet F, Tardy J, Albucher J-F, Thalamas E, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10:123–30. DOI: 10.1016/S1474-4422(10)70314-8
4. Mead G, Hackett ML, Lundstrom E, Murray V, Hankey GJ, Dennis M. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials. Trials. 2015;16(1):369. DOI: 10.1186/s13063-015-0864-1
5. FOCUS trial collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet. 2019;393:265–74. DOI: 10.1016/S0140-6736(18)32823-X
6. AFFINITY trial collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19:651–60. DOI: 10.1016/S1474-4422(20)30207-6
7. EFFECTS trial collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19:661–9. DOI: 10.1016/S1474-4422(20)30219-2
8. Mead GE, Hsieh CF, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, Hackett ML. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012;11:CD009286. 10.1002/14651858.CD009286.pub2. DOI: 10.1002/14651858.CD009286.pub2
9. Marquez-Romero JM, Arauz A, Ruiz-Sandoval JL, Cruz-Estrada Ede L, Huerta-Franco MR, Aguayo-Leytte G, Ruiz-Franco A, Silos H. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial. Trials. 2013;14:77. 10.1186/1745-6215-14-77. DOI: 10.1186/1745-6215-14-77
10. Mead GE, Legg L, Tilney R, Hsieh CF, Wu S, Lundström E, Rudbert AS, Kutlubaev M, Dennis MS, Soleimani B, Barugh A, Hackett ML, Hankey GJ. Fluoxetine for stroke recovery: meta-analysis of randomised controlled trials. Int J Stroke. 2019. 10.1177/1747493019879655.
11. Legg LA, Tilney R, Hsieh CF, Wu S, Lundström E, Rudberg AS, Kutlubaev MA, Dennis M, Soleimani B, Barugh A, Hackett ML, Hankey GJ, Mead GE. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2019;(Issue 11):CD009286. 10.1002/14651858.CD009286.pub3.
12. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221. 10.1136/bmj.c221. DOI: 10.1136/bmj.c221
13. Graham C, Lewis S, Forbes J, Mead G, Hackett ML, Hankey GJ, Gommans J, Nguyen HT, Lundström E, Isaksson E, Näsman P, Rudberg AS, Dennis M. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials. 2017;18(1):627. 10.1186/s13063-017-2385-6. DOI: 10.1186/s13063-017-2385-6
14. Athey S, Imbens G. Recursive partitioning for heterogeneous causal effects. Proc Natl Acad Sci U S A. 2016;113(27):7353–60. DOI: 10.1073/pnas.1510489113
15. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. DOI: 10.1136/bmj.l4898
16. Tierney JF, Vale C, Riley R, Catrin TS, Stewart L, Clarke M, Rovers M. Individual participant data (IPDM) meta-analyses of randomised controlled trials: guidance on their use. PLoS Med. 2015;12(7):e1001855. DOI: 10.1371/journal.pmed.1001855
17. Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts. BMC Med Res Methodol. 2017;17(162). 10.1186/s12874-017-0442-1.
18. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J Clin Epidemiol. 2011;64(4):407–15. DOI: 10.1016/j.jclinepi.2010.07.017
19. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPDM statement. JAMA. 2015;313(16):1657–65. 10.1001/jama.2015.3656. DOI: 10.1001/jama.2015.3656
20. McDermid I, Barber M, Dennis M, Langhorne P, Macleod MJ, McAlpine CH, Quinn TJ. Home-time is a feasible and valid stroke outcome measure in national datasets originally. Stroke. 2019;50:1282–5. DOI: 10.1161/STROKEAHA.118.023916